Eli Lilly and Company (LLY)vsRigel Pharmaceuticals Inc (RIGL)
LLY
Eli Lilly and Company
$1,131.42
-0.26%
HEALTHCARE · Cap: $948.95B
RIGL
Rigel Pharmaceuticals Inc
$29.93
-1.06%
HEALTHCARE · Cap: $593.55M
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 24002% more annual revenue ($72.25B vs $299.77M). RIGL leads profitability with a 121.5% profit margin vs 35.0%. RIGL trades at a lower P/E of 1.7x. LLY earns a higher WallStSmart Score of 78/100 (B+).
LLY
Strong Buy78
out of 100
Grade: B+
RIGL
Strong Buy65
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LLY.
Margin of Safety
+87.7%
Fair Value
$283.28
Current Price
$29.93
$253.35 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 81 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 49.4%
Revenue surging 55.5% year-over-year
Earnings expanding 169.9% YoY
Attractively priced relative to earnings
Reasonable price relative to book value
Every $100 of equity generates 91 in profit
Keeps 122 of every $100 in revenue as profit
Conservative balance sheet, low leverage
Strong operational efficiency at 20.2%
Areas to Watch
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 32.4x book value
Smaller company, higher risk/reward
Earnings declined 30.2%
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.
Bull Case : RIGL
The strongest argument for RIGL centers on P/E Ratio, Price/Book, Return on Equity. Profitability is solid with margins at 121.5% and operating margin at 20.2%. Revenue growth of 10.3% demonstrates continued momentum.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book.
Bear Case : RIGL
The primary concerns for RIGL are Market Cap, EPS Growth, Altman Z-Score.
Key Dynamics to Monitor
LLY profiles as a growth stock while RIGL is a mature play — different risk/reward profiles.
RIGL carries more volatility with a beta of 1.18 — expect wider price swings.
LLY is growing revenue faster at 55.5% — sustainability is the question.
LLY generates stronger free cash flow (3.0B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (78/100 vs 65/100), backed by strong 35.0% margins and 55.5% revenue growth. RIGL offers better value entry with a 87.7% margin of safety. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Rigel Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat blood disorders, cancer, and rare immune diseases. The company is headquartered in South San Francisco, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?